Advertisement

Topics

CANbridge pays $30mm up front for rights to Puma's Nerlynx

14:40 EST 5 Feb 2018 | Elsevier Business Intelligence

Puma Biotechnology Inc. granted CANbridge Life Sciences Ltd. exclusive rights to develop and sell its breast cancer therapy N...

Original Article: CANbridge pays $30mm up front for rights to Puma's Nerlynx

NEXT ARTICLE

More From BioPortfolio on "CANbridge pays $30mm up front for rights to Puma's Nerlynx"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...